Skip to main content
spacbrain

OmniAb

Closed (deSPAC)

Health Care · antibody discovery platform technology

What it is
OmniAb, Inc.’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics
What it’s doing now
Merging with Avista Public Acquisition Corp. II (AHPA) — closed (despac).
What you should know
Data is still being assembled for this company — what is shown below is everything we have verified so far.

The business, per its filings

SEC primary

OmniAb, Inc.’s discovery platform provides pharmaceutical industry partners access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence ™ (BI) of our proprietary transgenic animals, including OmniRat ® , OmniChicken ® and OmniMouse ® that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic ® (transgenic rat) and OmniClic ® (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur ™ features unique structural attributes of cow antibodies for complex targets. We believe the OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities in emerging target classes. OmniAb antibodies have been leveraged across modalities, including bispecific antibodies, antibody-drug conjugates and others. The OmniAb suite of technologies span from BI-powered repertoire generation to cutting edge antibody discovery and optimization offering a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please vis

Source: S-4/A, accession 0001104659-22-103339

What the company says about itself

Web research — not audited

OmniAb is a therapeutic antibody discovery company that provides pharmaceutical industry partners with access to diverse antibody repertoires and cutting-edge screening technologies. The company offers proprietary transgenic animal platforms (including OmniRat, OmniChicken, OmniMouse, OmniFlic, OmniClic, OmnidAb, OmniUltra, and OmniTaur) for generating human antibodies and peptides, as well as xPloration, an AI-powered B-cell screening technology.

Markets:
Therapeutic Antibody Discovery | Biotechnology
Products:
OmniRat | OmniChicken | OmniMouse | OmniFlic | OmniClic | OmnidAb | OmniUltra | OmniTaur | xPloration | picobodies
Customers:
Janssen
What our web check found

[WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "OmniAb expects to have approximately $95 million in cash at closing." [https://www.avistahealthcare.com/news_item/omniab-announces-completion-of-spin-off-and-business-combination/] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "The transaction is expected to be closed in the second half of 2022." [https://finance.yahoo.com/news/ligand-lgnd-inks-merger-deal-143902574.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Begins November 2, 2022." [https://www.avistahealthcare.com/news_item/omniab-announces-completion-of-spin-off-and-business-combination/]

Source: https://www.omniab.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.

The deal it’s entering

OmniAb is merging with Avista Public Acquisition Corp. II (AHPA) currently marked Closed (deSPAC).

Headline equity value—
PIPE≈ $100M · unsourced

Structure per SEC accession(s) 0001104659-22-051436. How to read these numbers: headline vs effective valuation · what a definitive agreement commits

What exactly is being valued, and at what

Common questions

Is OmniAb going public?

OmniAb has an approved merger with the SPAC Avista Public Acquisition Corp. II (AHPA). Deal status: Closed (deSPAC).

Does OmniAb have revenue?

The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.

Educational content, not investment advice.

Other health care deals